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Abstract
Background: In the chronic kidney disease (CKD) population, the impact of serum potassium (sK) on renal outcomes has
been controversial. Moreover, the reasons for the potential prognostic value of hypokalemia have not been elucidated.
Design, Participants & Measurements: 2500 participants with CKD stage 1–4 in the Integrated CKD care program
Kaohsiung for delaying Dialysis (ICKD) prospective observational study were analyzed and followed up for 2.7 years.
Generalized additive model was fitted to determine the cutpoints and the U-shape association between sK and end-stage
renal disease (ESRD). sK was classified into five groups with the cutpoints of 3.5, 4, 4.5 and 5 mEq/L. Cox proportional hazard
regression models predicting the outcomes were used.
Results: The mean age was 62.4 years, mean sK level was 4.260.5 mEq/L and average eGFR was 40.6 ml/min per 1.73 m
2.
Female vs male, diuretic use vs. non-use, hypertension, higher eGFR, bicarbonate, CRP and hemoglobin levels significantly
correlated with hypokalemia. In patients with lower sK, nephrotic range proteinuria, and hypoalbuminemia were more
prevalent but the use of RAS (renin-angiotensin system) inhibitors was less frequent. Hypokalemia was significantly
associated with ESRD with hazard ratios (HRs) of 1.82 (95% CI, 1.03–3.22) in sK ,3.5mEq/L and 1.67 (95% CI,1.19–2.35) in
sK=3.5–4 mEq/L, respectively, compared with sK=4.5–5 mEq/L. Hyperkalemia defined as sK .5 mEq/L conferred 1.6-fold
(95% CI,1.09–2.34) increased risk of ESRD compared with sK=4.5–5 mEq/L. Hypokalemia was also associated with rapid
decline of renal function defined as eGFR slope below 20% of the distribution range.
Conclusion: In conclusion, both hypokalemia and hyperkalemia are associated with increased risk of ESRD in CKD
population. Hypokalemia is related to increased use of diuretics, decreased use of RAS blockade and malnutrition, all of
which may impose additive deleterious effects on renal outcomes.
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Introduction
The kidney plays a major role in potassium homeostasis by
renal mechanisms that transport and regulate potassium secretion,
reabsorption and excretion [1]. Hyperkalemia is a common
electrolyte disturbance in patients with chronic kidney disease
(CKD) [2]. As eGFR decreases from above 60 to below 20 ml/
min/1.73 m
2, the prevalence of hyperkalemia increases from 2 to
42% [3]. In CKD individuals, a few studies suggested weak links
between hyperkalemia and ESRD [4,5].
Chronic hypokalemia, on the other hand, has been reported to
enhance renal cytogenesis and may lead to interstitial scarring and
renal insufficiency [6,7]. Recently, in CKD patients comorbid with
and without cardiovascular diseases, the associations between
hypokalemia and death as well as ESRD have been proposed
[4,5,8]. One paper demonstrated hypokalemia was associated with
ESRD but this effect was attenuated after adjusting nutritional
indices in patients with CKD stage 3 to 5 [4]. Another study
suggested hypokalemia was associated with renal progression but
the association with hard renal outcome, such as reaching ESRD
was unclear [5].
Recent studies have reported common predispositions such as
diabetes, high dietary potassium and renin-angiotensin-aldoste-
rone system blockers use for the development of hyperkalemia in
pateints with impaired renal functions [9–12]. Kaliuretic diuretics
such as furosemide and thiazides are common causes of
hypokalemia [13,14]. Diarrhea, vomiting, hyperaldosteronism,
magnesium deficiency and potassium redistribution induced by
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prerequisites for hypokalemia [15]. However, studies on hypoka-
lemia and aforementioned associated factors were done mostly in
general population. Moreover, the possible complex interplay
between hypokalemia, its associating factors and renal outcomes
has not been investigated.
In the CKD population, whether sK level is associated with
greater risks of renal outcomes has not been clearly defined.
Moreover, the verification of the reasons for the potential
prognostic value of hypokalemia remains to be elucidated. Thus,
we investigated the contributing factors of hypokalemia and
whether hyperkalemia or hypokalemia is a risk factor for adverse
renal outcomes in patients with CKD stage 1 to 4.
Methods
Participants and Measurement
Integrated CKD care program Kaohsiung for delaying Dialysis
(ICKD) study was designed as a prospective cohort to investigate
the impact of integrated CKD care program on clinical outcomes
from a diverse group of CKD stage 1–5 patients. The included
population was CKD patients not on renal replacement therapy.
The exclusion criterion was acute kidney injury defined as more
than 50% decrease in eGFR in three months. The study recruited
patients from the nephrology out-patient departments of two
hospitals in southern Taiwan. Between November 11, 2002 and
May 31, 2009, 3749 patients received integrated CKD care
program and were followed up until July 31, 2010. 90 patients
were lost for follow-ups in less than 3 months and 1159 stage
5 CKD patients were excluded. Total 2500 subjects with CKD
stage 1 to 4 were analyzed. The study protocol was approved by
the institutional review board of the Kaohsiung Medical Univer-
sity Hospital (KMUH-IRB-990198). Informed consents have been
obtained in written form from patients and all clinical investigation
was conducted according to the principles expressed in the
Declaration of Helsinki. The patients gave consent for the
publication of the clinical details.
At the baseline visit, socio-demographic characteristics, medical
history, lifestyle behaviors and current medications were recorded.
The medical history was confirmed by doctors’ chart-review.
Diabetes mellitus (DM) and hypertension were defined by clinical
diagnosis. Cardiovascular disease (CVD) was defined as clinical
diagnosis of heart failure, acute or chronic ischemic heart disease,
or cerebrovascular disease. Body Mass Index (BMI) was calculated
from the baseline enrolled measurement using the formula: weight
in kilograms/(height in meters)
2. Mean blood pressure (MBP) was
calculated by the averages of systolic and diastolic BP measured 3
months before and after the enrollment using the formula: 2/3
average systolic BP +1/3 average diastolic BP.
Biochemistry measurements were done on screening visit,
baseline visit and then every 3 months as the protocol. The
laboratory data from 3 months before baseline visit to 3 months
after baseline visit were averaged and analyzed. Six-month
averaged sK was used for analysis and was classified into five
groups as sK ,3.5; K=3.5–4; K=4–4.5, K=4.5–5 and K
.5 mEq/L. The cutpoints were defined by generalized additive
regression. Serum creatinine, albumin, cholesterol, C-reactive
protein (CRP), potassium and phosphate levels were determined
by means of the Toshiba TBA C16000 chemistry analyzer. Serum
hemoglobin was determined by means of the Sysmex XE-2100
automated hematology analyzer. HbA1C was measured by
Primus CLC 385 automated analyzer. Venous blood bicarbonate
was measured by AVL Omni 3 blood gas analyzer.
Quantification of Renal Function and Progression
Kidney function was quantified by using the estimated
glomerular filtration rate (eGFR) derived from the simplified
Modification of Diet in Renal Disease (MDRD) Study equation.
The equation was eGFR ml/min/1.73 m
2=186 6 Serum
creatinine
21.154 6 Age
20.203 6 0.742 (if female) 6 1.212 (if
black patient). The average eGFR slope (ml/min/1.73 m
2/yr) for
each patient was calculated by linear regression with varying-
intercept and varying-slope without co-variates for estimation of
the annual change of eGFR.
Outcomes
Renal outcomes were assessed: end stage renal disease (ESRD)
and rapid renal progression. ESRD was defined as the initiation of
hemodialysis, peritoneal dialysis or renal transplantation. The
initiation of renal replacement therapy was discovered by review of
charts or catastrophic cards. Rapid renal progression was defined
as an eGFR slope,26.88 ml/min/1.73 m
2/yr which was the
20th percentile. Other cut-off values were also applied in
sensitivity tests. The timing for ESRD was according to the
regulation of Bureau of the National Health Insurance of Taiwan
regarding the laboratory data, nutritional status, uremic status and
serum creatinine (.6 mg/dL). ESRD was ascertained by review-
ing charts and by matching with the database from Taiwan
Society of Nephrology.
Statistical Analysis
Statistic results of baseline characteristics of all subjects were
expressed as percentages for categorical variables, mean 6
standard deviation (SD) for continuous variables with approxi-
mately-normal distribution, and median and interquartile range
for continuous variables with skewed distribution.
We conducted both linear regression and generalized additive
models (GAM) to investigate the variables associated with sK.
GAM were fitted to detect nonlinear effects of continuous
covariates (VGAM function of the VGAM package) [16,17] for
sK because GAM were developed for smoothing the effects of
covariates in generalized linear models. The selection of variables
was based on previous models and also the nutritional and
medication variables that we hypothesized.
Cox proportional hazards models were used to evaluate
association of variables with time to ESRD. Covariates included
in these models were age, gender, DM, CVD, eGFR, Urine
protein by dipstick, Angiotensin-converting enzyme inhibitor
(ACEI), Angiotensin II receptor blocker (ARB), diuretics, MBP,
BMI, HbA1c, log-transformed cholesterol, log-transformed CRP,
phosphate, hemoglobin and albumin. Generalized additive models
with restricted cubic regression splines were used to explore the
functional form of the relationship between sK and ESRD. The
knots for sK were at 4.03 and 5.11 mEq/L and we thus divided sK
accordingly in the tables. Binary logistic regression analysis was
used to assess the relationship between sK and rapid renal
progression. Covariates included into these models were the same
as those in Cox regression.
Also, the statistical tools for regression diagnostics such as
verification of proportional hazards assumption, residual analysis,
detection of influential cases, and check for multicollinearity were
applied to discover model or data problems. Statistical analysis was
performed using the R 2.15.2 software (R Foundation for
Statistical Computing, Vienna, Austria) and Statistical Package
for Social Sciences version 18.0 for Windows (SPSS Inc., Chicago,
IL).
Hypokalemia and Renal Outcomes in CKD Patients
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Baseline Characteristics of CKD Patients Divided by
Serum Potassium Quintiles
A total of 2500 participants in CKD stage 1–4 were analyzed
during a median 2.7-year of follow-up. Figure 1 displayed the
distribution of five sK groups by CKD stage 1–4. There was still
5.6% of participants with sK ,3.5 mEq/L in those with CKD
stage 4, while there was less than 1% of patients with sK .5 mEq/
L in those with CKD stage 1. The majority of the participants
were male (64%), had hypertension (61.5%) with a mean age of
62.4614.5 years, mean sK of 4.260.5 mEq/L and mean eGFR of
40.6623.3 ml/min/1.73 m
2 (Table 1). Patients with lower sK
were more likely to have hypertension, higher eGFR, higher
serum hemoglobin, cholesterol and bicarbonate levels, whereas
they were less likely to have a history of diabetes, to have higher
HbA1c and phosphate levels, in comparison with those with
higher sK. Figure 2 further demonstrated the relationship between
sK and other important predictive covariates. There were higher
proportions of patients presenting with hypoalbuminemia
(,3.5 mg/dL) and lower BMI (20 kg/m
2) in the groups with sK
,3.5 and .5mEq/L (Figure 2A).
In total participants, ESRD rate was 43 per 1000 person-years
(Table 1). There was a trend of greater crude rates of ESRD and
steeper decline in eGFR in groups with higher sK. There were no
significant univariate linear relationships between sK groups and
rapid renal progression and increment of proteinuria respectively.
However, greater increase of proteinuria and higher proportion of
participants with rapid renal progression were observed in the
groups with sK ,3.5 mEq/L and sK .5 mEq/L with p for Chi-
Square as p=0.009 and p,0.001 respectively.
The percentages of patients receiving ACEI, ARB, oral
hypoglycemic agents and insulin were higher in those with more
elevated sK (Table 2). The proportions of other medication use
such as furosemide, thiazide, phosphate binder and b-blocker did
not show significant trends among groups. Despite similar MBP
across five groups of sK, the use of anti-hypertensive medication
was less frequent while the use of diuretics was more prevalent as
sK decreased (Figure 2B). The prevalence of nephrotic range
proteinuria was the highest in the groups with sK ,3.5 and
.5 mEq/L but the use of RAS inhibitors was the least in sK
,3.5 mEq/L (Figure 2C).
All the univariate significant and non-significant but relevant
covariates were tested in multivariate linear regression for sK
(Table 3). Non-linear effects of continuous variables were tested by
generalized additive models (Table S1 and Figure S1). sK was
negatively correlated with eGFR, MBP, bicarbonate, CRP and
hemoglobin and positively correlated with HbA1c and albumin.
The use of ACEI, ARB, and insulin vs those non-users were
associated with higher sK. Female vs. male and diuretics users vs.
non-users were associated with lower sK (Table 3 and Table S1).
Potassium and Renal Replacement Therapy
There were 299 patients (12%) reaching ESRD during a
median 2.7-year of follow-up. To explore the non-linear associ-
ation of sK and ESRD, we fitted a generalized additive model with
a restricted cubic spline regression (Figure 3). The result revealed a
U-shaped association, with increased risk of ESRD when sK
,4.03 mEq/L and sK .5.11 mEq/L. Consistent with these
associations, when compared to sK=4.5–5mEq/L, both sK
,3.5 mEq/L and sK=3.5–4 mEq/L were significantly associated
with 82% (HR 1.82; CI 95% 1.03–3.22; p=0.041) and 67% (HR
1.67; CI 95% 1.19–2.35; p=0.003) excess risk of ESRD,
respectively in fully-adjusted Cox regression (Table 4). sK
.5mEq/L was also associated with increased risk of becoming
ESRD with HR of 1.60 (CI 95% 1.09–2.34).
Other risk factors for ESRD revealed in the multivariate Cox
regression analysis included diabetes, decreased eGFR, diuretic
use, higher MBP, proteinuria (by dipstick or by urine protein-to-
creatinine ratio (UPCR)), hyperphosphatemia, higher HbA1c,
lower BMI, anemia and hypoalbuminemia (Table 4). We also
tested the proportional hazard assumption and linearity assump-
tion. The results were shown in Supplementary Table 2. Three
variables including gender, albumin and bicarbonate were against
proportional hazard assumption and were treated by stratification.
Four variables including serum potassium, BMI, mean blood
pressure and C-reactive protein had non-linear relationships with
ESRD (Table S2 and Figure S2). An alternative model with
UPCR showed similar results (data not shown).
Subgroup Analysis for Hypokalemia and Renal
Replacement Therapy
The association between the sK ,3.5mEq/L and ESRD was
significant in patients with ARB use (HR 3.14; 1.36–7.24;
p,0.001), but not in those without (HR 1.32; 0.58–2.97;
p=0.508; p for interaction, 0.041). The other pre-specified
subgroups did not show significant interaction.
Potassium and Rapid Renal Progression
The median eGFR slope was 21.8 ml/min/1.73 m
2/yr. There
were 492 participants (20%) experiencing eGFR slope less than
26.88 ml/min/1.73 m
2/yr. Serum K lower than 3.5 mEq/L was
significantly associated with faster yearly decline in eGFR with
odds ratio (OR) of 1.69 (CI 95% 1.06–2.70; p=0.027) compared
with sK=4.5–5 mEq/L after full adjustment (Table 4). On the
other hand, sK .5mEq/L didn’t show significant association with
rapid progression of renal function. Additional risk factors for
rapid renal progression included diabetes, higher MBP, less ARB
use, proteinuria, hyperphosphatemia, higher HbA1c, anemia and
hypoalbuminemia.
Discussion
In our cohort, we examined the associations between sK, its
associating factors and renal outcomes in 2500 patients with CKD
stage 1–4. We demonstrated that diuretic use vs. non-use,
hypertension, higher bicarbonate, hemoglobin and CRP levels
significantly correlated with hypokalemia. The use of ACEI, ARB,
Figure 1. Serum Potassium Distribution by Chronic Kidney
Disease (CKD) Stages.
doi:10.1371/journal.pone.0067140.g001
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PLOS ONE | www.plosone.org 4 July 2013 | Volume 8 | Issue 7 | e67140Figure 2. The Relationships between Serum Potassium and
Other Predictive Covariates. Figure 2A. Percentages of malnutrition
indices including serum albumin lower than 3.5 mg/dL and body mass
index (BMI) less than 20 kg/m
2 across potassium groups. Figure 2B.
Proportions of diuretics use (Thiazide and/or Furosemide use), anti-
hypertensive (anti-HTN) medication and mean blood pressure (MBP)
across potassium groups. Figure 2C. Proportions of ACEI, ARB and
proteinuria with nephrotic range across potassium groups. ACEI,
angiotensin-converting enzyme inhibitor; ARB, angiotensin II receptor
blocker; UPCR, Urine protein-to-creatinine ratio. P-values were gener-
ated by chi-square tests.
doi:10.1371/journal.pone.0067140.g002
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PLOS ONE | www.plosone.org 5 July 2013 | Volume 8 | Issue 7 | e67140and insulin vs. those non-users, higher HbA1c and albumin levels
were associated with higher sK. The association of sK with rapid
renal progression and ESRD was U shape. Hypokalemia defined
as ,4 mEq/L and hyperkalemia as .5 mEq/L in our cohort
were significantly associated with greater risk of ESRD.
Our results found hypokalemia to be a significant indicator of
renal progression in CKD evidenced by 82% increased risk of
reaching ESRD, rapid annual decline in eGFR and increase of
proteinuria in CKD population. Our results are in accordance
with a study of 1227 males with CKD by Kovesdy et al. They
found that a sK ,3.6 mEq/L was associated with more severe
progression (–0.23 ml/min/1.73 m
2/yr, p=0.002) compared to
sK=3.6–5.5 [5]. On the contrary, Saran et al. reported that the
association between hypokalemia (,4 mEq/L) and ESRD disap-
peared after adjustment for serum albumin. In our studies, we
proposed that insufficient anti-hypertensive medication, increased
diuretic use, insufficient RAS inhibition and malnutrition associ-
ated with hypokalemia could be related with worse outcomes.
We propose the following as plausible mechanisms: First, less
use of anti-hypertensive medication despite similar BP and greater
diuretic use were associated with hypokalemia (Fig. 2B, and
Table 3). Diuretics are often used in patients with heart and/or
renal disease with volume overload. However, chronic diuretic use
has been reported to be associated with higher long-term mortality
and hospitalization for HF [18]. Our study (Table 4) as well as
clinical studies and animal models have suggested a correlation
between diuretic use and progression of renal disease [19].
Thiazides have been proposed to associate with renal injury via
the induction of hypokalemia, metabolic abnormalities, and
volume depletion and to lead to additional focal glomerular
damage not observed in states of equivalent hypokalemia in the
absence of diuretics [20].
Second, inadequate RAS inhibition related to either insufficient
RAS blockade or resistance to RAS inhibitors may be related to
hypokalemia. Insufficient RAS blockage was suggested by a
greater extent of proteinuria and less use of ACEI/ARB in the
hypokalemic population (Fig. 2C). There is well-established
evidence that RAS inhibitors (ACEI or ARB) have beneficial
effects on renal outcomes in both diabetic kidney disease and non-
diabetic patients with proteinuria [21,22]. However, in the
subgroup of ARB use in our cohort, hypokalemia was still
associated with increased risk of ESRD. Previous studies had
shown that ACE insertion/deletion (I/D) polymorphism contrib-
uted to the variability in ACEI treatment response and sodium-
potassium balance [23–25]. The Antihypertensive and Lipid-
Lowering Treatment to Prevent Heart Attack Trial (ALLHAT)
reported the associations of mortality with new-onset hypokalemia
(,3.5 mEq/L) and hyperkalemia (.5.4 mEq/L) determined at
year-1 of treatment with chlorthalidone, lisinopril or amlodipine
[26]. The risk of mortality among participants who developed
hypokalemia by year 1 in the Lisinopril group was the highest (HR
3.825; CI: 2.26–6.44; P,0.001) than in either of the other 2
groups. From our result and previous reports, hypokalemia might
be related to poor response to RAS blockade.
Third, hypoalbuminemia and lower BMI were associated with
hypokalemia (Fig. 2A, Table 3). Hypoalbuminemia, as a marker of
both nutritional and inflammatory status was associated with an
increased rate of mortality in the population with renal disease
[27–29]. Hypokalemia might also be a surrogate marker of
malnutrition and correlated with hypoalbuminemia in both
peritoneal and hemodialysis patients [30–32]. Both hypoalbumin-
Table 3. Linear Regression of Serum Potassium.
Multivariate linear regression
Variables Beta coefficient 95% CI Beta coefficient p
constant 4.83
Gender (female) 20.13 20.18 to 20.09 ,0.001
GFR per 10 mL/min/1.73 m
2 20.03 20.04 to 20.02 ,0.001
ACEI user vs non-user 0.05 0.005 to 0.09 0.026
ARB user vs non-user 0.06 0.02 to 0.10 0.007
Diuretics use vs non-user 20.13 20.18 to 20.08 ,0.001
Bicarbonate (mEq/L) 20.03 20.03 to 20.02 ,0.001
Phosphorus (mg/dL) 0.08 0.05 to 0.10 ,0.001
Log-transformed CRP 20.05 20.07 to 20.03 ,0.001
HbA1c (%)
In total population 0.02 0.01 to 0.04 0.001
In HbA1c ,10% group* 0.044 0.025 to 0.064 ,0.001
In HbA1c §10% group* 20.081 20.141 to 20.021 0.008
Hemoglobin (g/dL) 20.03 20.04 to 20.01 ,0.001
Albumin (g/dL)
In total population 0.09 0.05 to 0.14 ,0.001
In albumin ,4 g/dL group* 0.161 0.096 to 0.225 ,0.001
In albumin §4 g/dL group* 20.156 20.288 to 20.024 0.021
MBP (mmHg) 20.002 20.004 to 20.001 0.002
Insulin user vs non-user 0.15 0.07 to 0.24 ,0.001
ACEI, angiotensin-converting enzyme inhibitor; ARB, angiotensin II receptor blocker.
MBP, mean blood pressure; eGFR, estimated glomerular filtration rate; CRP, C-reactive protein; HbA1c, glycated hemoglobin; UPCR, Urine protein-to-creatinine ratio.
All relevant variables were tested. Variables with significance were presented. * segmental linear regression with the same variables.
doi:10.1371/journal.pone.0067140.t003
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renal outcomes when included simultaneously in the Cox
regression model (Table 4). These findings may point out that
hypokalemia is an independent risk factor for CKD progression
and indicates additional prognostic importance of hypoalbumin-
emia.
Significant correlations between hypokalemia and alkalosis and
hypertension respectively were observed (Table 3). Hypokalemia
related augmented ammoniagenesis and subsequent renal injury
has been documented [33]. Hypokalemia was also reported to
stimulate renin and angiotensin II despite direct suppression of
aldosterone synthesis leading to salt-sensitive hypertension, intra-
renal vasoconstriction and ischemia [34–37]. Other mechanisms
mediating renal injury in hypokalemia such as increased
inflammatory mediators, oxidative stress [38] and impaired
angiogenesis [39] have been reported. Human and animal
pathologic studies also demonstrated that prolonged hypokalemia
was accompanied by development of multiple renal medullary
cysts, tubular degeneration, marked interstitial fibrosis and intense
macrophage infiltration eventually leading to the impairment of
renal function [6,40].
Hyperkalemia, beginning with serum values greater than
.5 mEq//L in our cohort was associated with higher risk of
ESRD. Recent post-hoc analysis of the RENAAL trial of Type 2
diabetes mellitus, by De Zeeuw et al. reported that increased sK
$5 mEq/L after treatment with Losartan was associated with
increased risk of ESRD. One potential mechanism could be the
vicious cycle of increasing aldosterone levels in response to
sustained hyperkalemia [41]. Aldosterone has been proposed to
cause renal progression through both hemodynamic effects and
direct cellular actions as it promotes endothelial dysfunction,
facilitates thrombosis, reduces vascular compliance and causes
myocardial and vascular fibrosis [42,43].
Our study has limitations to be considered. As an observational
cohort, our ability to elucidate the definite causal links was limited.
The variation of sK levels affected by nutritional status or
medication use during the follow-up period could confound the
results. However, the average sK level is a more precise
description of baseline status than the single measurement mostly
used in published studies. Even with markers of nutritional status
such as serum albumin and BMI, lack of records of dietary intake
might still confound the findings. Only a small group of patients in
the sK ,3.5 group had rapid progression (26.2%) and incident
ESRD (8.2%). These patients also presented heavier proteinuria at
baseline. We attempted to account for the differences in baseline
proteinura in our adjusted models. However, residual confounding
by factors related to the underlying kidney diseases in these
patients might still remain. This also limits our ability to make
Figure 3. Restricted Cubic Spline Regression Plot of the U-shape Association between sK and the Risk for End Stage Renal Disease.
Covariates included in the model were the same as the Cox regression in Table 4. Serum potassium (sK), body mass index, mean blood pressure and
C-reactive protein were treated as restricted cubic spline functions. The solid line represents the log transformed multivariable-adjusted hazard ratio
of ESRD. The dashed lines indicate the 95% confidence intervals. sK below 4.03 and above 5.11 mEq/L were associated with higher hazard (log hazard
ratio .0). Tick marks on the x-axis indicate individual observations at corresponding levels of sK.
doi:10.1371/journal.pone.0067140.g003
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renal outcomes. Finally, the follow-up period of 2.7 years could be
relatively short for the assessment of progression to ESRD,
especially for our study participants with higher eGFR. However,
other indicators of renal progression such as the eGFR slope and
proteinuria were examined and all pointed to the associations
between worse renal outcomes and hypo- and hyperkalemia.
In conclusion, both hypokalemia and hyperkalemia are
associated with elevated risk of developing ESRD in a CKD
population. Hypokalemia is related to increased use of diuretics,
decreased use of RAS blockade and malnutrition, all of which may
impose additive deleterious effects on renal outcomes. Clinical
implication may be drawn from our study that sK should be
routinely evaluated and special attention given for sK between
3.5–4 mEq/L, generally considered as low ‘‘normal’’. However,
further clinical trials are required to determine if interventions
aimed at achieving optimal sK level will slow the progression
towards ESRD.
Supporting Information
Figure S1 Restricted Cubic Spline Regression Model of
the Non-linear Effect of BMI, HbA1c and Albumin on sK.
A. Body Mass Index (BMI) below 16.4 and above 36.1 kg/m
2
were associated with higher sK. Tick marks on the x-axis indicate
individual observations at corresponding levels of BMI. The solid
line represents the log transformed predictive value of serum
potassium (sK). Same annotations were used for Figure S1B and
S1C. B. HbA1c below 6.69 and above 12.79% were associated
with higher sK. C. Albumin below 3.68 and above 4.56 mg/dL
were associated with higher sK.
(TIF)
Figure S2 Restricted Cubic Spline Regression Model of
theHazardRatioof sK, BMI, MBPandCRP forEndStage
Renal Disease. A. Serum potassium (sK) below 4.03 and above
5.11 mEq/L wereassociated with higherhazard. Tick marks on the
x-axisindicateindividualobservationsat corresponding levelsof sK.
The solid line represents the log transformed multivariable-adjusted
hazard ratio of ESRD. Same annotations were used for Figure S2B,
S2C and S2D. B. Body Mass Index (BMI) below 23.36 and between
29.68 and 39.49 kg/m
2 were associated with higher hazard for
ESRD. C. Mean blood pressure (MBP) below 72.27 and between
101.16 and 127.66 mmHg were associated with higher hazard for
ESRD. D. C-reactive protein (CRP) below 39.36 mg/L was
associated with higher hazard for ESRD.
(TIF)
Table S1
(DOC)
Table S2
(DOC)
Table 4. Association of Categorical Potassium with ESRD and Rapid Renal Progression in Full-Adjusted Model.
ESRD Rapid renal progression*
Risk factors HR (95% CI) p OR (95% CI) p
constant 2.71 3.04
Diabetes mellitus 1.57 (1.19 to 2.08) 0.001 1.30 (1.00 to 1.69) 0.047
eGFR ml/min/1.73 m
2 0.92 (0.90 to 0.93) ,0.001 1.02 (1.01 to 1.02) ,0.001
Proteinuria by dipstick
2 1(reference) 1(reference)
+ 2.06 (1.26 to 3.35) 0.004 1.44 (1.02 to 2.02) 0.036
++ 4.11 (2.61 to 6.47) ,0.001 2.86 (2.04 to 3.99) ,0.001
+++,++++ 7.50 (4.73 to 11.88) ,0.001 4.83 (3.34 to 6.95) ,0.001
ARB user vs non-user 0.88 (0.69 to 1.12) 0.312 0.69 (0.55 to 0.89) 0.004
Diuretics user vs non-user 1.44 (1.07 to 1.93) 0.015 1.14 (0.85 to 1.53) 0.386
Potassium
sK ,3.5 mEq/L 1.82 (1.03 to 3.22) 0.041 1.69 (1.06 to 2.70) 0.027
sK=3.524 mEq/L 1.67 (1.19 to 2.35) 0.003 1.18 (0.83 to 1.66) 0.364
sK=424.5 mEq/L 1.23 (0.89 to 1.70) 0.205 1.12 (0.82 to 1.55) 0.470
sK=4.525 mEq/L 1 (reference) 1 (reference)
sK .5 mEq/L 1.60 (1.09 to 2.34) 0.016 1.39 (0.89 to 2.20) 0.149
Body mass index (kg/m
2) 0.96 (0.94 to 0.99) 0.016 0.97 (0.95 to 1.00) 0.072
MBP (mmHg) 1.01 (1.00 to 1.02) 0.019 1.01 (1.01 to 1.02) 0.001
Phosphorus (mg/dL) 1.36 (1.20 to 1.54) ,0.001 1.21 (1.05 to 1.39) 0.008
HbA1c (%) 1.09 (1.02 to 1.17) 0.013 1.10 (1.03 to 1.18) 0.004
Hemoglobin (g/dL) 0.85 (0.79 to 0.92) ,0.001 0.82 (0.77 to 0.88) ,0.001
Albumin (g/dL) 0.45 (0.36 to 0.57) ,0.001 0.61 (0.49 to 0.77) ,0.001
*eGFR slope less than 26.88 ml/min/1.73 m
2/yr.
Values expressed as hazard ratio (95% confidence interval) [HR (95% CI)] and odds ratio (95% confidence interval) [OR (95% CI)].
Full-adjusted model included age, gender, DM, CVD, eGFR, Urine protein by dipstick, ACEI, ARB, diuretics, MBP, BMI, HbA1c, log-transformed cholesterol, log-
transformed CRP, phosphate, hemoglobin and albumin. Variables with significance were presented.
doi:10.1371/journal.pone.0067140.t004
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